Name: Cagrilintide

Alias: AM833, Long-acting Amylin Analog, DACRA CAS Registry number: 1415456-99-3 Sequence: (Eicosanedioic acid-γ-Glu)-KCNTATCATQRLAEFLRHSSNNFGILPPTNVSGTP-NH? (Disulfide bridge: Cys3-Cys8) Molecular Formula: C???H???N??O??S? Molecular Weight: 4409.01 Da Purity: ≥99% (by HPLC) Appearance: White lyophilized powder Packing: 10 vials/box (10mg total per vial) Product Group: Long-acting dual amylin & calcitonin receptor agonist peptide

Storage Conditions: Store at -20℃ in a dry, dark place; avoid repeated freeze-thaw cycles.

Brief Introduction:

Cagrilintide is a lipidated long-acting synthetic amylin analog exclusively for laboratory research. It acts as a dual agonist targeting amylin and calcitonin receptors, with fatty acid acylation modification to bind albumin and greatly prolong in-vivo half-life. It slows gastric emptying, enhances central satiety signal, reduces food intake, stabilizes blood glucose levels and lowers visceral fat accumulation. It synergizes well with GLP-1 agonists to improve metabolic homeostasis, widely applied in obesity, type 2 diabetes, energy balance and metabolic combination drug research.

Main Research Applications:

Satiety & appetite regulation research: Used in cell and animal models to study central amylin receptor signaling and feeding inhibition mechanisms. Glucose homeostasis research: Suitable for exploring gastric emptying delay, postprandial blood glucose control and insulin demand reduction pathways. Weight & adipose metabolism research: Applied to investigate visceral fat reduction, body weight loss and lipid metabolism remodeling effects. Dual receptor pharmacology research: For comparative analysis of amylin/calcitonin dual activation and downstream metabolic signal cascade.

Combination peptide research: Study synergistic weight-lowering and hypoglycemic effects when compounded with GLP-1 analogs such as Semaglutide.